N-3 polyunsaturated fatty acids reduces post-operative atrial fibrillation incidence in patients undergoing â€œon-pumpâ€ coronary artery bypass graft surgery
AbstractBackground: The aim of this study was to evaluate the efficacy of preoperative and postoperative therapy with n-3 polyunsaturated fatty acids in reducing the incidence of atrial fibrillation after coronary artery bypass graft surgery. Methods: 201 patients undergoing coronary artery bypass graft surgery were randomized to 1) a control group (105 patients), or 2) n-3 polyunsaturated fatty acids 2 g/day group (96 patients) for at least 5 days before surgery and until hospital discharge. Groups were further subdivided in four subgroups according to the operative technique: â€œoff-pumpâ€ or â€œon-pumpâ€. The primary end point was to evaluate the reduced incidence of postoperative in-hospital atrial fibrillation in the (N-3 PUFA) group. Secondary end points were the impact of the surgical technique on the incidence of postoperative arrhythmia and the impact of n-3 polyunsaturated fatty acids therapy on post-operative hospital length of stay. Results: The overall incidence of post-operative atrial fibrillation was 17.4% (35/201). The arrhythmia occurred in 11.4% (11/96) of the patients in therapy with n-3 polyunsaturated fatty acids and in 22.8% (24/105) in the control groups. In particular, the statistical analysis of subgroups showed a significant reduction of postoperative atrial fibrillation only in the group including patients treated with n-3 polyunsaturated fatty acids undergoing â€œon-pumpâ€ coronary artery bypass graft surgery. The length of hospital stay did not differ among all groups. Conclusions: N-3 polyunsaturated fatty acids administration significantly reduces the incidence of post-operative atrial fibrillation in patients undergoing â€œon-pumpâ€ coronary artery bypass graft surgery. N-3 polyunsaturated fatty acids therapy is not associated with a shorter hospital stay.
- Abstract views: 879
- PDF: 557
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.